Lisatoclax plus chemo for untreated DLBCL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug called Lisatoclax added to standard chemotherapy (R-CHOP or Pola-R-CHP) for people with untreated diffuse large B-cell lymphoma (DLBCL). It aims to see if the combination works better and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with DLBCL (a type of blood cancer) that has not been treated before.
- You are between 18 and 70 years old.
- Your overall health is good enough for standard activities (ECOG score 0-2).
- Your organs (like liver, kidneys, bone marrow) are working well.
- You have at least one tumor that can be measured on a scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called birelentinib combined with standard chemotherapy (R-CHOP) for people who have just been diagnosed with a type of lymphoma called DLBCL. The goal is to see if the combination works better than R-CHOP alone.
This trial tests a new drug called glofitamab combined with standard Pola-R-CHP chemotherapy for people with untreated DLBCL. The goal is to see if using PET scans and blood tests early on can guide treatment and improve outcomes.
This trial tests a combination of three drugs (lisaftoclax, chidamide, and rituximab) for patients with diffuse large B-cell lymphoma that has come back or stopped responding to previous treatments. The goal is to see if this combination can help patients whose disease hasn't responded to standard chemotherapy and who aren't candidates for stem cell transplant.
This study tests whether adding a drug called trilaciclib to standard chemotherapy can help people with newly diagnosed Diffuse Large B-Cell Lymphoma. It aims to see if this combination keeps blood counts healthier and improves treatment outcomes.
This trial tests a new combination of drugs (chidamide, lisaftoclax, and standard chemotherapy) to treat a serious type of blood cancer called double-hit or triple-hit diffuse large B-cell lymphoma. The goal is to see if adding these newer drugs to standard treatment improves how well the cancer responds.
This trial tests a combination of three drugs—pirtobrutinib, lisaftoclax, and rituximab—for people with relapsed or refractory DLBCL who have already had at least one prior treatment. The goal is to see if this combination can help shrink or control the lymphoma.
Hear when a new Diffuse Large B Cell Lymphoma (DLBCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.